Molecular Oncogenesis

  • Jennifer L. Hunt
Part of the Molecular Pathology Library book series (MPLB, volume 3)


Oncogenesis in all organ systems is generally considered to be an extremely complex process, with poorly understood etiology and drivers. There is substantial evidence that much of carcinogenesis is driven by changes at the molecular level, at the DNA, RNA, or the protein expression level. New evidence also suggests that alterations in small RNA molecules (microRNA) can contribute to carcinogenesis, though this process is incompletely understood. Finally, environmental, nutritional, and external factors are almost certainly linked to carcinogenesis in some organ systems. It is precisely because of the complexity in all of these widely divergent drivers of carcinogenesis that we continue to search for the causes of cancer in most organ systems.


Thyroid Cancer Familial Adenomatous Polyposis Short Tandem Repeat Paraffin Embed Tissue Short Tandem Repeat Locus 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Antonescu CR. Targeted therapies in gastrointestinal stromal tumors. Semin Diagn Pathol. 2008;25:295–303.CrossRefPubMedGoogle Scholar
  2. 2.
    Assaad A, Voeghtly L, Hunt JL. Thyroidectomies from patients with history of therapeutic radiation during childhood and adolescence have a unique mutational profile. Mod Pathol. 2008;21:1176–1182.CrossRefPubMedGoogle Scholar
  3. 3.
    Bogdanova TI, Zurnadzhy LY, Greenebaum E, et al. A cohort study of thyroid cancer and other thyroid diseases after the Chornobyl accident: pathology analysis of thyroid cancer cases in Ukraine detected during the first screening (1998-2000). Cancer. 2006;107:2559–2566.CrossRefPubMedGoogle Scholar
  4. 4.
    Bounacer A, Wicker R, Caillou B, et al. High prevalence of activating ret proto-oncogene rearrangements, in thyroid tumors from patients who had received external radiation. Oncogene. 1997;15:1263–1273.CrossRefPubMedGoogle Scholar
  5. 5.
    Cohen J. Genes and behavior make an appearance in the O. J. trial. Science. 1995;268:22–23.CrossRefPubMedGoogle Scholar
  6. 6.
    Collins BJ, Schneider AB, Prinz RA, Xu X. Low frequency of BRAF mutations in adult patients with papillary thyroid cancers following childhood radiation exposure. Thyroid. 2006;16:61–66.CrossRefPubMedGoogle Scholar
  7. 7.
    Engelman JA, Janne PA. Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. 2008;14:2895–2899.CrossRefPubMedGoogle Scholar
  8. 8.
    Fearon ER, Hamilton SR, Vogelstein B. Clonal analysis of human colorectal tumors. Science. 1987;238:193–197.CrossRefPubMedGoogle Scholar
  9. 9.
    Fugazzola L, Pierotti MA, Vigano E, Pacini F, Vorontsova TV, Bongarzone I. Molecular and biochemical analysis of RET/PTC4, a novel oncogenic rearrangement between RET and ELE1 genes, in a post-Chernobyl papillary thyroid cancer. Oncogene. 1996;13:1093–1097.PubMedGoogle Scholar
  10. 10.
    Fujiyama A, Watanabe H, Toyoda A, et al. Construction and analysis of a human-chimpanzee comparative clone map. Science. 2002;295:131–134.CrossRefPubMedGoogle Scholar
  11. 11.
    Fukui T, Ohe Y, Tsuta K, et al. Prospective study of the accuracy of EGFR mutational analysis by high-resolution melting analysis in small samples obtained from patients with non-small cell lung cancer. Clin Cancer Res. 2008;14:4751–4757.CrossRefPubMedGoogle Scholar
  12. 12.
    Georgiou M, Hatzaki A, Koutselinis A. Identification of an alleged offender of murder by VNTR analysis: case report. Am J Forensic Med Pathol. 2000;21:162–165.CrossRefPubMedGoogle Scholar
  13. 13.
    Grubwieser P, Zimmermann B, Niederstatter H, Pavlic M, Steinlechner M, Parson W. Evaluation of an extended set of 15 candidate STR loci for paternity and kinship analysis in an Austrian population sample. Int J Legal Med. 2007;121(2):85–89.CrossRefPubMedGoogle Scholar
  14. 14.
    Heinrich MC, Maki RG, Corless CL, et al. Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor. J Clin Oncol. 2008;26:5352–5359.CrossRefPubMedGoogle Scholar
  15. 15.
    Heinrich MC, Owzar K, Corless CL, et al. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26:5360–5367.CrossRefPubMedGoogle Scholar
  16. 16.
    Hunt JL. Molecular pathology in anatomic pathology practice: a review of basic principles. Arch Pathol Lab Med. 2008;132:248–260.PubMedGoogle Scholar
  17. 17.
    Hunt JL, Finkelstein SD. Microdissection techniques for molecular testing in surgical pathology. Arch Pathol Lab Med. 2004;128:1372–1378.PubMedGoogle Scholar
  18. 18.
    Hunt JL, Swalsky P, Sasatomi E, Niehouse L, Bakker A, Finkelstein SD. A microdissection and molecular genotyping assay to confirm the identity of tissue floaters in paraffin-embedded tissue blocks. Arch Pathol Lab Med. 2003;127:213–217.PubMedGoogle Scholar
  19. 19.
    Iwasa Y, Michor F, Komarova NL, Nowak MA. Population genetics of tumor suppressor genes. J Theor Biol. 2005;233:15–23.CrossRefPubMedGoogle Scholar
  20. 20.
    Judson IR. Prognosis, imatinib dose, and benefit of sunitinib in GIST: knowing the genotype. J Clin Oncol. 2008;26:5322–5325.CrossRefPubMedGoogle Scholar
  21. 21.
    Knudson AG Jr. Genetics and the etiology of childhood cancer. Pediatr Res. 1976;10:513–517.CrossRefPubMedGoogle Scholar
  22. 22.
    Knudson AG Jr, Strong LC. Mutation and cancer: a model for Wilms’ tumor of the kidney. J Natl Cancer Inst. 1972;48:313–324.PubMedGoogle Scholar
  23. 23.
    Nikiforov Y, Gnepp DR. Pediatric thyroid cancer after the Chernobyl disaster. Pathomorphologic study of 84 cases (1991-1992) from the Republic of Belarus. Cancer. 1994;74:748–766.CrossRefPubMedGoogle Scholar
  24. 24.
    Nikiforov YE, Rowland JM, Bove KE, Monforte-Munoz H, Fagin JA. Distinct pattern of ret oncogene rearrangements in morphological variants of radiation-induced and sporadic thyroid papillary carcinomas in children. Cancer Res. 1997;57:1690–1694.PubMedGoogle Scholar
  25. 25.
    Payne SR, Kemp CJ. Tumor suppressor genetics. Carcinogenesis. 2005;26:2031–2045.CrossRefPubMedGoogle Scholar
  26. 26.
    Rubin BP, Duensing A. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab Invest. 2006;86:981–986.CrossRefPubMedGoogle Scholar
  27. 27.
    Sakaki Y, Watanabe H, Taylor T, et al. Human versus chimpanzee chromosome-wide sequence comparison and its evolutionary implication. Cold Spring Harb Symp Quant Biol. 2003;68:455–460.CrossRefPubMedGoogle Scholar
  28. 28.
    Sanchez JJ, Phillips C, Borsting C, et al. A multiplex assay with 52 single nucleotide polymorphisms for human identification. Electrophoresis. 2006;27:1713–1724.CrossRefPubMedGoogle Scholar
  29. 29.
    Schlumberger M, Cailleux AF, Suarez HG, de Vathaire F. Irradiation and second cancers. The thyroid as a case in point. C R Acad Sci III. 1999;322:205–213.PubMedGoogle Scholar
  30. 30.
    Sequist LV, Joshi VA, Janne PA, et al. Epidermal growth factor receptor mutation testing in the care of lung cancer patients. Clin Cancer Res. 2006;12:4403s-4408s.CrossRefPubMedGoogle Scholar
  31. 31.
    Shakhtarin VV, Tsyb AF, Stepanenko VF, Orlov MY, Kopecky KJ, Davis S. Iodine deficiency, radiation dose, and the risk of thyroid cancer among children and adolescents in the Bryansk region of Russia following the Chernobyl power station accident. Int J Epidemiol. 2003;32:584–591.CrossRefPubMedGoogle Scholar
  32. 32.
    Slebos RJ, Umbach DM, Sommer CA, Horner GA, Choi JY, Taylor JA. Analytical and statistical methods to evaluate microsatellite allelic imbalance in small amounts of DNA. Lab Invest. 2004;84:649–657.CrossRefPubMedGoogle Scholar
  33. 33.
    Staiti N, Di Martino D, Saravo L. A novel approach in personal identification from tissue samples undergone different processes through STR typing. Forensic Sci Int. 2004;146 Suppl:S171-S173.CrossRefPubMedGoogle Scholar
  34. 34.
    Sweet DJ, Sweet CH. DNA analysis of dental pulp to link incinerated remains of homicide victim to crime scene. J Forensic Sci. 1995;40:310–314.PubMedGoogle Scholar
  35. 35.
    Toth J, Egervari K, Klekner A, et al. Analysis of EGFR gene amplification. Protein over-expression and tyrosine kinase domain mutation in recurrent glioblastoma. Pathol Oncol Res. 2009;15(2):225–229.CrossRefPubMedGoogle Scholar
  36. 36.
    Tuttle RM, Becker DV. The Chernobyl accident and its consequences: update at the millennium. Semin Nucl Med. 2000;30:133–140.CrossRefPubMedGoogle Scholar
  37. 37.
    Vogelstein B, Fearon ER, Hamilton SR, et al. Genetic alterations during colorectal-tumor development. N Engl J Med. 1988;319:525–532.CrossRefPubMedGoogle Scholar
  38. 38.
    Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol. 2007;25:118–145.CrossRefPubMedGoogle Scholar
  39. 39.
    Yatabe Y, Takahashi T, Mitsudomi T. Epidermal growth factor receptor gene amplification is acquired in association with tumor progression of EGFR-mutated lung cancer. Cancer Res. 2008;68:2106–2111.CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2010

Authors and Affiliations

  • Jennifer L. Hunt
    • 1
  1. 1.Department of PathologyHarvard Medical School, Massachusetts General HospitalBostonUSA

Personalised recommendations